Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

Life Sciences (ATAI) announced that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral ...

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that it has dosed the first patient in the ...

Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the first ...

Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability ...

SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has ...

The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant ...

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...

today announced the first patient has been dosed in its first-in-human study evaluating ARC101, a potential best-in-class T cell engager targeting Claudin 6 (CLDN6). This Phase 1 study will ...